AZD-1480
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- AZD-1480
- DrugBank Accession Number
- DB12588
- Background
AZD1480 has been used in trials studying the treatment of Solid Malignancies, Post-Polycythaemia Vera, Primary Myelofibrosis (PMF), and Essential Thrombocythaemia Myelofibrosis.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 348.766
Monoisotopic: 348.1013984 - Chemical Formula
- C14H14ClFN8
- Synonyms
- Not Available
- External IDs
- AZD 1480
- AZD-1480
- AZD1480
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Halopyrimidines
- Alternative Parents
- Aminopyrimidines and derivatives / Imidolactams / Aryl fluorides / Aryl chlorides / Pyrazoles / Heteroaromatic compounds / Azacyclic compounds / Organofluorides / Organochlorides / Hydrocarbon derivatives show 1 more
- Substituents
- Amine / Aminopyrimidine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl fluoride / Aryl halide / Azacycle / Azole / Halopyrimidine / Heteroaromatic compound show 8 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- KL2Z2TLF01
- CAS number
- 935666-88-9
- InChI Key
- PDOQBOJDRPLBQU-QMMMGPOBSA-N
- InChI
- InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1
- IUPAC Name
- 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
- SMILES
- C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 16659841
- PubChem Substance
- 347828808
- ChemSpider
- 17592916
- BindingDB
- 50335201
- ChEMBL
- CHEMBL1231124
- ZINC
- ZINC000058631551
- PDBe Ligand
- AZ5
- PDB Entries
- 2xa4
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Other Essential Thrombocythaemia Myelofibrosis / Post Polycythemia Vera Myelofibrosis / Primary Myelofibrosis (PMF) 1 1 Terminated Treatment Advanced Malignant Solid Tumor / Child-Pugh A to B7 Advanced Hepatocellular Carcinoma / EGFR and/or ROS Mutant NSCLC / Gastric Cancer / Lung Metastasis Carcinoma / Solid Tumors 1 1 Terminated Treatment Solid Tumor Malignancies 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0284 mg/mL ALOGPS logP 2.75 ALOGPS logP 2.7 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 11.62 Chemaxon pKa (Strongest Basic) 3.08 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 104.3 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 91.12 m3·mol-1 Chemaxon Polarizability 33.8 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0002-9254000000-b7bbaa0e3fafad42bb91 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0019000000-9992afef448240ef4e28 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0119000000-17960d12b294135ea18c Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-002b-0029000000-99bbabdf0e218f8a1bfc Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-01rt-0894000000-796f371a81dbd3b99208 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-9533000000-a8040a30d367e0e5decb Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-007o-9682000000-cb215da8e4c7176f4867 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 179.10493 predictedDeepCCS 1.0 (2019) [M+H]+ 181.46294 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.5052 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 23:03 / Updated at June 12, 2020 16:53